Mirum Pharmaceuticals
950 Tower Lane, Suite 1050
Foster City
CA
94404
United States
Tel: 650-667-4085
Website: https://mirumpharma.com/
Email: info@mirumpharma.com
210 articles about Mirum Pharmaceuticals
-
Positive Topline Data Announced from Mirum’s LIVMARLI Phase 3 MARCH Study in Progressive Familial Intrahepatic Cholestasis (PFIC)
10/24/2022
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced positive topline results from its pivotal Phase 3 MARCH study evaluating LIVMARLI® (maralixibat) oral solution in 93 patients with progressive familial intrahepatic cholestasis (PFIC) in a broad range of subtypes, age one to 17 years.
-
Mirum Pharmaceuticals’ LIVMARLI Data Highlighting Quality of Life and Sleep Improvements in Patients with Alagille Syndrome Published in Journal of Pediatrics
10/18/2022
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that data highlighting quality of life and sleep improvements from its pivotal ICONIC study evaluating LIVMARLI® (maralixibat) oral solution in patients with Alagille syndrome (ALGS), were published in the Journal of Pediatrics.
-
Mirum Pharmaceuticals Announces Positive CHMP Opinion for LIVMARLI® (maralixibat) Oral Solution for Cholestatic Pruritus in Patients with Alagille Syndrome Two Months of Age and Older
10/14/2022
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced two global advancements for LIVMARLI® (maralixibat) oral solution, an oral minimally absorbed ileal bile acid transporter (IBAT) inhibitor currently approved in the U.S. for the treatment of cholestatic pruritus in patients with Alagille syndrome one year of age and older.
-
Mirum Pharmaceuticals Presents Long-Term LIVMARLI® (maralixibat) Data and New Alagille Syndrome Caregiver Burden Analysis at NASPGHAN 2022 Annual Meeting
10/12/2022
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) shared data from three posters presented during the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition Annual Meeting (NASPGHAN) taking place October 12-16, 2022, in Orlando, Florida.
-
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - October 11, 2022
10/11/2022
Mirum Pharmaceuticals, Inc. announced that on October 10, 2022, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 52,650 shares of common stock and 26,400 restricted stock units to nine new employees under Mirum’s 2020 Inducement Plan.
-
Mirum Pharmaceuticals to Present LIVMARLI® (maralixibat) Analyses and Host a Scientific Symposium at NASPGHAN 2022 Annual Meeting
10/5/2022
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will present three posters and host a scientific symposium during the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) Annual Meeting taking place October 12-16, 2022, in Orlando, Florida.
-
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - September 12, 2022
9/12/2022
Mirum Pharmaceuticals, Inc. announced that on September 10-11, 2022, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 47,750 shares of common stock and 23,900 restricted stock units to 11 new employees under Mirum’s 2020 Inducement Plan.
-
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences in September 2022
8/30/2022
Mirum Pharmaceuticals, Inc. announced that it will participate in the following upcoming investor conferences: Citi's 17th Annual BioPharma Conference on Wednesday, September 7, 2022.
-
Mirum Pharmaceuticals Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Common Stock - Aug 12, 2022
8/12/2022
Mirum Pharmaceuticals, Inc. announced the closing of its previously announced underwritten public offering of 4,000,000 shares of its common stock, including the exercise in full by the underwriters of their option to purchase an additional 521,739 shares, at a price to the public of $23.00 per share.
-
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Aug 11, 2022
8/11/2022
Mirum Pharmaceuticals, Inc. announced that on August 10, 2022, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 28,250 shares of common stock and 14,100 restricted stock units to eight new employees under Mirum’s 2020 Inducement Plan.
-
Mirum Pharmaceuticals Announces Pricing of Public Offering of Common Stock - Aug 10, 2022
8/10/2022
Mirum Pharmaceuticals, Inc., a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan diseases, announced the pricing of its previously announced underwritten public offering of 3,478,261 shares of its common stock at a price to the public of $23.00 per share.
-
Mirum Pharmaceuticals Announces Commencement of Public Offering of Common Stock - Aug 09, 2022
8/9/2022
Mirum Pharmaceuticals, Inc. announced that it has commenced an underwritten public offering, subject to market and other conditions, to issue and sell $80.0 million of shares of its common stock.
-
Mirum Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
8/4/2022
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today reported financial results for the second quarter ended June 30, 2022 and provided a business update.
-
Mirum Pharmaceuticals to Announce Second Quarter 2022 Financial Results and Host Conference Call on August 4, 2022
7/28/2022
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will report second quarter financial results on Thursday, August 4, 2022.
-
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - July 09, 2022
7/9/2022
Mirum Pharmaceuticals, Inc. announced that on July 8, 2022, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 43,000 shares of common stock and 21,500 restricted stock units to seven new employees under Mirum’s 2020 Inducement Plan.
-
Mirum Pharmaceuticals Presents New Data at The International Liver Congress™ of the European Association for the Study of the Liver (EASL)
6/24/2022
Mirum Pharmaceuticals, Inc. presented data at the International Liver Congress™ of The European Association for the Study of the Liver in London, United Kingdom.
-
Mirum Pharmaceuticals Highlights Data Demonstrating Impact of LIVMARLI® (maralixibat) on Patients with Alagille Syndrome at European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) Annual Meeting
6/24/2022
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) presented data from clinical programs evaluating maralixibat (LIVMARLI®) in patients with Alagille syndrome at the 54th Annual ESPGHAN Meeting.
-
Mirum Pharmaceuticals to Showcase LIVMARLI® (maralixibat) Data at EASL and ESPGHAN Annual Congresses
6/13/2022
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) will present data at the upcoming International Liver Congress™ of the European Association for the Study of the Liver.
-
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 11, 2022
6/11/2022
Mirum Pharmaceuticals, Inc. announced that on June 10, 2022, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 43,550 shares of common stock and 21,800 restricted stock units to 8 new employees under Mirum’s 2020 Inducement Plan.
-
Mirum Pharmaceuticals Appoints Saira Ramasastry to Board of Directors
6/6/2022
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced the appointment of Saira Ramasastry to the Company’s board of directors and as a member of the audit committee where she will bring to bear her more than 20 years of financial leadership.